NCT03578796Completed
Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen in Norway: A Prospective Cohort Study
Cognitive Impairment in ALS: Screening Tools, Experiences and Prognosis
Source: ClinicalTrials.gov · Last updated 6 Oct 2026
Brief summary (registry, in English)
This study evaluate use of a translated Norwegian version of the Edinburgh cognitive and behavioral amyotrophic lateral sclerosis screen (ECAS-N) as an early predictor in car-driving, working and use of advanced life-prolonging therapy.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 31 (actual)
- First submitted
- 1 Jun 2018
- Start date
- 1 May 2017
- Primary completion date
- 31 Dec 2022
- Lead sponsor
- Haukeland University Hospital
- Diseases
- ALS (motor neurone disease)
- NCT number
- NCT03578796
What you commit to
- Study type: Observational
- Participants enrolled: 31
- From 1 May 2017 to the primary completion date, 31 Dec 2022
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Neurological disorders others than ALS
- Psychiatric history of importance to cognitive function
Other
- Great difficulties in writing or reading
- Comorbid medical history
Who the study is looking for
- Voluntary informed consent
- Native Norwegian speaker
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Haukeland University Hospital Coordinator of this site? Confirm its status | Bergen | Norway | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.